Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis.

[1]  L. Brinton,et al.  Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years , 2009, Cancer Epidemiology Biomarkers & Prevention.

[2]  R. Kennedy,et al.  BRCA1 and implications for response to chemotherapy in ovarian cancer. , 2009, Gynecologic oncology.

[3]  J. Chang-Claude,et al.  Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[4]  B. Henderson,et al.  Effect of Reproductive Factors and Oral Contraceptives on Breast Cancer Risk in BRCA1/2 Mutation Carriers and Noncarriers: Results from a Population-Based Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[5]  Christopher I Amos,et al.  Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  V. Beral,et al.  Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87 303 controls , 2008, The Lancet.

[7]  J. Chang-Claude,et al.  Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Whittemore,et al.  BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50 , 2006, Cancer Epidemiology Biomarkers & Prevention.

[9]  M. Papa,et al.  Hormone replacement therapy is more prevalent among Jewish BRCA1/2 mutation carriers. , 2006, European journal of cancer.

[10]  J. Krischer,et al.  BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.

[11]  Å. Borg,et al.  Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. , 2005, European journal of cancer.

[12]  A. Whittemore,et al.  Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations , 2004, British Journal of Cancer.

[13]  A. Whittemore,et al.  Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. , 2004, American journal of epidemiology.

[14]  M. King,et al.  Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 , 2003, Science.

[15]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[16]  D. Fishman,et al.  Reproductive factors and ovarian cancer risk in Jewish BRCA1 and BRCA2 mutation carriers (United States) , 2003, Cancer Causes & Control.

[17]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[18]  F. Couch,et al.  Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. , 2002, Journal of the National Cancer Institute.

[19]  Douglas G Altman,et al.  Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta‐epidemiological’ research , 2002, Statistics in medicine.

[20]  K. Heimdal,et al.  Oral contraceptives and risk of familial breast cancer. , 2002, Cancer detection and prevention.

[21]  Theo Stijnen,et al.  Advanced methods in meta‐analysis: multivariate approach and meta‐regression , 2002, Statistics in medicine.

[22]  O. Olopade,et al.  Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. , 2001, Pharmacogenetics.

[23]  J Q Shi,et al.  A sensitivity analysis for publication bias in systematic reviews , 2001, Statistical methods in medical research.

[24]  S Wacholder,et al.  Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[25]  K. Shojania,et al.  Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. , 2001, Effective clinical practice : ECP.

[26]  T. Key,et al.  Epidemiology of breast cancer. , 2001, The Lancet. Oncology.

[27]  J. Boyd.  BRCA: the breast, ovarian, and other cancer genes. , 2001, Gynecologic oncology.

[28]  S D Walter,et al.  A comparison of methods to detect publication bias in meta‐analysis , 2001, Statistics in medicine.

[29]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[30]  D. Fishman,et al.  BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. , 2000, American journal of human genetics.

[31]  S. Nilsson,et al.  Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence , 1998, Clinical endocrinology.

[32]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1997 .

[33]  B. Henderson,et al.  Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? , 1997, Cancer research.

[34]  D E Goldgar,et al.  Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. , 1997, American journal of human genetics.

[35]  S. Sharp,et al.  Explaining heterogeneity in meta-analysis: a comparison of methods. , 1997, Statistics in medicine.

[36]  P. Hartge,et al.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. , 1997, The New England journal of medicine.

[37]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies , 1996, The Lancet.

[38]  D. Easton,et al.  Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[39]  R. Brian Haynes,et al.  Developing optimal search strategies for detecting clinically sound studies in MEDLINE. , 1994, Journal of the American Medical Informatics Association : JAMIA.

[40]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[41]  C. Johannes,et al.  Re: "Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women". , 1993, American journal of epidemiology.

[42]  A. Whittemore,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[43]  J Halpern,et al.  Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. I. Methods. Collaborative Ovarian Cancer Group. , 1992, American journal of epidemiology.

[44]  S. Greenland,et al.  Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. , 1992, American journal of epidemiology.

[45]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[46]  G. W. Snedecor.  STATISTICAL METHODS , 1967 .

[47]  D. Fishman,et al.  Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. , 2007, The Lancet. Oncology.

[48]  J. Lubiński,et al.  Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland , 2005, Breast Cancer Research and Treatment.

[49]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.